Overview

Safety and Tolerability of Single Ascending Intravenous (IV) Doses of REGN5381 in Adult Heart Failure Patients With Elevated Pulmonary Capillary Wedge Pressure and Reduced Left Ventricular Ejection Fraction

Status:
Not yet recruiting
Trial end date:
2023-10-04
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of single doses of REGN5381 in patients with heart failure and reduced left ventricular ejection fraction (LVEF) with evidence of congestion The secondary objectives of the study are to: - Evaluate the effects of single doses of REGN5381 on hemodynamic parameters - Evaluate the effects of REGN5381 on a clinical biomarker of heart failure severity - Characterize the pharmacokinetics (PK) of single doses of REGN5381 - Assess the immunogenicity of REGN5381
Phase:
Phase 2
Details
Lead Sponsor:
Regeneron Pharmaceuticals